Neurological Disease News and Research RSS Feed - Neurological Disease News and Research

Scientists redraw traditional brain map of language comprehension

Scientists redraw traditional brain map of language comprehension

For 140 years, scientists' understanding of language comprehension in the brain came from individuals with stroke. Based on language impairments caused by stroke, scientists believed a single area of the brain -- a hotdog shaped section in the temporal lobe of the left hemisphere called Wernicke's region -- was the center of language comprehension. [More]
MedDay announces additional positive results from MD1003 Phase III trial in patients with progressive MS

MedDay announces additional positive results from MD1003 Phase III trial in patients with progressive MS

MedDay, a biotechnology company focused on the treatment of nervous system disorders, reports additional positive data from its pivotal Phase III clinical trial, MS-SPI, with MD1003, a highly-concentrated pharmaceutical grade biotin, in patients with Progressive Multiple Sclerosis. [More]
Study opens door to deeper understanding of genetic, molecular aspects underlying sleep disorders

Study opens door to deeper understanding of genetic, molecular aspects underlying sleep disorders

Washington State University Spokane scientists have grown a tiny group of brain cells that can be induced to fall asleep, wake up and even show rebound sleep after "staying up late." [More]
ASCO 2015: Novartis presents data on Zykadia and Tafinlar studies for non-small cell lung cancer

ASCO 2015: Novartis presents data on Zykadia and Tafinlar studies for non-small cell lung cancer

Novartis today announced new data from two Phase II studies of Zykadia (ceritinib), as well as one Phase II study of Tafinlar® (dabrafenib) in combination with Mekinist (trametinib) in certain patients with non-small cell lung cancer. [More]
Novartis CTL019 CAR T cell therapy demonstrates potential to treat B-cell lymphomas

Novartis CTL019 CAR T cell therapy demonstrates potential to treat B-cell lymphomas

Novartis is highlighting data from an ongoing Phase II clinical study of CTL019, an investigational chimeric antigen receptor (CAR) T cell therapy, that indicate its potential in the treatment of specific types of hard-to-treat non-Hodgkin lymphoma. [More]
Key lifestyle changes could help reduce risk of cognitive decline

Key lifestyle changes could help reduce risk of cognitive decline

The evidence is mounting: People can reduce their risk of cognitive decline by making key lifestyle changes. That is the conclusion of a new research summary published online today in Alzheimer's & Dementia: The Journal of the Alzheimer's Association. [More]
Combination of Mekinist and Tafinlar drugs improves outcome in patients with metastatic melanoma

Combination of Mekinist and Tafinlar drugs improves outcome in patients with metastatic melanoma

Novartis today announced data from the Phase III COMBI-d study showing a significant survival benefit for patients with BRAF V600E/K mutation-positive metastatic melanoma when treated with the combination of Tafinlar (dabrafenib) and Mekinist (trametinib) compared to Tafinlar monotherapy alone. [More]
Scientists develop human cortical spheroids

Scientists develop human cortical spheroids

A patient tormented by suicidal thoughts gives his psychiatrist a few strands of his hair. She derives stem cells from them to grow budding brain tissue harboring the secrets of his unique illness in a petri dish. She uses the information to genetically engineer a personalized treatment to correct his brain circuit functioning. Just Sci-fi? Yes, but... [More]
Novartis to highlight strength of its expanded oncology portfolio at ASCO 2015

Novartis to highlight strength of its expanded oncology portfolio at ASCO 2015

Novartis will highlight the strength of its expanded oncology portfolio in 21 medicines and 11 investigational compounds across more than 185 data presentations at the upcoming American Society of Clinical Oncology (ASCO) Annual Meeting, May 29-June 2, and the Congress of the European Hematology Association (EHA), June 11-14. [More]
Study shows how people's expectation of pain affects the experience of pain

Study shows how people's expectation of pain affects the experience of pain

Picture yourself in a medical office, anxiously awaiting your annual flu shot. The nurse casually states, "This won't hurt a bit." But when the needle pierces your skin it hurts, and it hurts a lot. Your expectations have been violated, and not in a good way. [More]
Mayo Clinic scientists create mouse model of ALS, FTD caused by mutations in C9ORF72 gene

Mayo Clinic scientists create mouse model of ALS, FTD caused by mutations in C9ORF72 gene

Scientists at Mayo Clinic, Jacksonville, Florida created a novel mouse that exhibits the symptoms and neurodegeneration associated with the most common genetic forms of frontotemporal dementia (FTD) and amyotrophic lateral sclerosis (ALS, Lou Gehrig's disease), both of which are caused by a mutation in the a gene called C9ORF72. [More]
Researchers find that blocking MCAM molecule could slow progression of multiple sclerosis

Researchers find that blocking MCAM molecule could slow progression of multiple sclerosis

A drug that could halt the progression of multiple sclerosis may soon be developed thanks to a discovery by a team at the CHUM Research Centre and the University of Montreal. The researchers have identified a molecule called MCAM, and they have shown that blocking this molecule could delay the onset of the disease and significantly slow its progression. [More]
MRI screening helps in accurate and rapid stroke treatment

MRI screening helps in accurate and rapid stroke treatment

Time is critical when it comes to stroke, and early treatment is associated with better outcomes. According to the Screening with MRI for Accurate and Rapid stroke Treatment (SMART) study, small changes in quality improvement procedures enabled clinicians to use MRI scans to diagnose stroke patients before giving acute treatment, within 60 minutes of hospital arrival. [More]
Scientists uncover mechanism behind 'tubulin code'

Scientists uncover mechanism behind 'tubulin code'

Driving down the highway, you encounter ever-changing signs -- speed limits, exits, food and gas options. Seeing these roadside markers may cause you to slow down, change lanes or start thinking about lunch. In a similar way, cellular structures called microtubules are tagged with a variety of chemical markers that can influence cell functions. [More]

Wearable cognitive assessment devices a step closer as Cambridge Cognition file new patents

The combination of bio-behavioural measures and results from touch-screen cognitive tests would be used to build up a picture of a person’s mental function... [More]
Findings provide glimmer of hope for treating diffuse intrinsic pontine gliomas

Findings provide glimmer of hope for treating diffuse intrinsic pontine gliomas

Using brain tumor samples collected from children in the United States and Europe, an international team of scientists found that the drug panobinostat and similar gene regulating drugs may be effective at treating diffuse intrinsic pontine gliomas (DIPG), an aggressive and lethal form of pediatric cancer. [More]
NPC recognized as top ranking company on DiversityInc Top 50 Companies for Diversity list

NPC recognized as top ranking company on DiversityInc Top 50 Companies for Diversity list

Novartis Pharmaceuticals Corporation has been named the top company for diversity for the second year in a row on the annual DiversityInc Top 50 Companies for Diversity listing. DiversityInc announced the results of its 2015 Top 50 Companies for Diversity on April 23 at an awards ceremony in New York, NY. [More]
Two existing drugs may potentially become new drug target for multiple sclerosis

Two existing drugs may potentially become new drug target for multiple sclerosis

Two drugs already on the market -- an antifungal and a steroid -- may potentially take on new roles as treatments for multiple sclerosis. According to a study published in Nature today, researchers discovered that these drugs may activate stem cells in the brain to stimulate myelin producing cells and repair white matter, which is damaged in multiple sclerosis. [More]
Plymouth researchers receive grant to develop effective therapy for Huntington's disease

Plymouth researchers receive grant to develop effective therapy for Huntington's disease

Huntington's disease is an hereditary disorder of the nervous system caused by a faulty gene on chromosome four. The faulty gene leads to nerve damage in the area of the brain resulting in gradual physical, mental and emotional changes. Those born to a parent with Huntington's disease have a 50:50 chance of developing it, and there is currently no cure. [More]
Patient's own skin cells may hold key to new treatments for neurological diseases

Patient's own skin cells may hold key to new treatments for neurological diseases

A patient's very own skin cells may hold the key to new treatments and even cures for devastating neurological diseases. A generous $1 million donation from Mr. J. Sebastian van Berkom, and critical partnerships with Brain Canada, Laval University, Marigold Foundation and the FRQS-Réseau Parkinson Quebec are driving an innovative, iPSC (induced pluripotent stem cell) research platform that will transform research into Parkinson's and other neurological diseases. [More]
Advertisement
Advertisement